PAIP2B

Across TCGA pan-cancer cohorts, PAIP2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAIP2B data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PAIP2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PAIP2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where PAIP2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	1.000	0.532	.007	29	view →
CCRCC	OS	Median	All	1.000	0.674	.009	16	view →
UCEC	DFS	Median	All	0.935	1.000	.020	8	view →
HNSC	DFS	Tertile	All	0.884	0.333	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAIP2B–LUAD (DFS)

Open the LUAD breakdown →